Business Wire

TX-MAVENIR

24.3.2021 14:02:05 CET | Business Wire | Press release

Share
Mavenir Awarded ‘Best Open RAN Technology’ and ‘Best Telecom Service Innovation’ for Fully Containerized, Cloud-Native at 5G MENA Awards

Mavenir, the industry’s only end-to-end cloud-native Network Software Provider and a leader in accelerating software network transformation for communications service providers (CSPs), was recognized for “Best Telecom Service Innovation” for its innovation in the delivery of fully containerized, cloud-native IMS as well as “Best Open RAN Technology” for its Virtualized Open RAN at the 5G Middle East and North Africa (MENA) Digital Symposium virtual awards.

Both awards are a demonstration of Mavenir’s dedication to developing innovative solutions for CSPs as they roll out 5G networks, achieve web-scale economics, increase productivity, and leverage current network investments.

“In order to rise to the challenges and demands operators face, Mavenir recognizes that cloud-native architecture and open interfaces are the only way forward, minimizing human intervention and driving efficient resource utilization,” said Mark Charman, Mavenir’s VP Middle East and Africa, who accepted the award. “Mavenir is honored to be recognized for our technology and innovation and our commitment for the advancement of software driven, cloud native telecoms solutions in the MENA region.”

Presenting the awards, Srushti Ghisad, Research Manager from Omdia said: “Mavenir's world’s first fully containerized, virtualized Open RAN has the flexibility to support various deployment scenarios - the main objective behind Open RAN - with clear commercial benefits. Mavenir's fully containerized cloud-native IMS demonstrates scalability, flexibility, and most importantly automation.”

Mavenir’s fully containerized, OpenRAN vRAN solution enables operators to rapidly deploy new features into the network, without waiting for new hardware revisions, or even having to forklift the hardware. It is easy to migrate from 4G to 5G with just a software update, and operators can customize their own software and put features of their choice in their network.

As the #1 IMS provider of NFV IMS, voice, video, and messaging, Mavenir transforms mobile networks with a fully virtualized and containerized cloud-native IMS platform where devices, applications, and services can run on an automated network using open architecture, containers, and artificial intelligence.

The 5G MENA awards , organized by Informa Tech, is an annual celebration of excellence and innovation in the MENA Region, held virtually on 22 March 2021 to award the most innovative and cutting-edge solutions for 5G core technology, RAN, and service innovation.

About Mavenir:

Mavenir is the industry's only end-to-end, cloud-native Network Software and Solutions/Systems Integration Provider, focused on accelerating software network transformation. Mavenir offers a comprehensive end-to-end product portfolio across every layer of the network infrastructure stack for communications service providers and enterprises. From 5G application layers (VoLTE, Messaging) to Packet Core and RAN, Security, Edge Analytics and AI, Mavenir leads the way in evolved, cloud-native networking solutions enabling innovative and secure experiences for end users.

Leveraging innovations in Mobile Core with IMS (VoLTE, VoWiFi, Advanced Messaging/RCS), and Packet Core (vEPC, 5G Core) as well as Radio Access/Edge (OpenRAN), Private Networks, as well as Mobile Services and Applications such as Digital Enablement. Mavenir accelerates digital network transformation for more than 250+ CSP customers in over 120 countries, which serve over 50% of the world’s subscribers. www.mavenir.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Strike Europe Secures Full MiCA Authorization, Unlocking Bitcoin Services Across All 27 EU Member States30.6.2026 13:29:00 CEST | Press release

Strike is now available to millions of customers across the European Union Strike, a leading Bitcoin financial services company, today announced that its European entity, Zap (Strike) Europe Limited, has been authorized as a crypto-asset service provider by the Malta Financial Services Authority (MFSA) under the EU's Markets in Crypto-Assets Regulation (MiCA) and the Malta Markets in Crypto Assets Act (Cap. 647, laws of Malta) to provide crypto-asset services. The license enables millions of Europeans across all 27 EU member states to access Strike's suite of Bitcoin financial services under a single regulatory framework, replacing the patchwork of national regimes that previously governed the market. Strike has served eligible European customers since April 2024. The MFSA authorization makes that presence permanent and EU-wide, and positions the company among a small group of firms to complete the MiCA process to date. "Europe deserves a Bitcoin-only company focused on doing one thing

OpZira, Inc. Welcomes Scott Thielman, PhD, as Vice President of Product Development30.6.2026 13:17:00 CEST | Press release

OpZira™, Inc., a forward-thinking ophthalmic medical device company founded on a legacy of research excellence, today announced that Scott Thielman, PhD, PE, has joined the company as Vice President of Product Development, effective May 1, 2026. Dr. Thielman brings a unique connection to OpZira’s origins. As Chief Technology Officer of Product Creation Studio, he directed the product development of LumiThera’s Valeda® Light Delivery System - the breakthrough photobiomodulation therapy for dry age-related macular degeneration whose acquisition by Alcon led to the creation of OpZira. His involvement with Valeda gives him firsthand knowledge of the science, clinical vision, and engineering decisions that shaped the technology platform from which OpZira was born. For more than 25 years, Dr. Thielman has directed the development of dozens of FDA-cleared medical devices across ophthalmology, neurostimulation, dermatology, urology, and surgical instrumentation, with partners including Olympus

L&T Technology Services Launches Ainfonix™ 4.0 to Unlock Engineering Intelligence Across Process Industries30.6.2026 12:45:00 CEST | Press release

The enterprise AI platform turns millions of engineering artifacts that run a plant into accurate, decision-ready data, delivering up to 85% extraction accuracy and full, audit-ready traceability L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of Ainfonix™ 4.0, a next-generation Engineering Intelligence platform for process industries. Unveiled at EI Live, LTTS’ flagship event that brings together analysts, industry leaders and engineering experts, Ainfonix™ 4.0 marks an important step in the company’s Enterprise AI and Engineering Intelligence strategy. As industrial enterprises accelerate AI adoption, decades of engineering knowledge remain trapped in fragmented drawings, specifications and technical records across disparate systems. Without trusted and accessible engineering data, organizations struggle to realize the full value of AI, automation and digital transformation

Klick Health Acquires Oxford PharmaGenesis, Bringing Together Unsurpassed Scientific-to-Commercial Capabilities for Life Sciences Clients30.6.2026 12:03:00 CEST | Press release

Bonded by breakthroughs and a laser focus on their people and clients, leading independent agencies join forces to deliver accelerated commercial success through broadened medical affairs and communications, market access, and RWE/HEOR offerings; the most advanced degree holders; expanded global reach; and the best workplace culture around Focused on taking life sciences companies into the future, Klick Health today announced its acquisition of Oxford PharmaGenesis, the market-leading HealthScience communications consultancy renowned for its scientific and medical expertise, as well as value and market access consulting throughout Europe, Asia-Pacific, and North America. Today’s news brings together two of the leading independent agencies in life sciences. With Oxford PharmaGenesis’ expertise across medical affairs and market access, and Klick's strength in commercial strategy, medical, creative, digital, analytics, and experience design, they can deliver an unparalleled scientific-to-

BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma30.6.2026 12:00:00 CEST | Press release

Foundational BTKi BRUKINSA plus rituximab reduced the risk of progression or death by 43% versus bendamustine plus rituximab (HR=0.57; p<0.0001), meeting the primary endpoint of PFSMANGROVE is the first Phase 3 trial to advance a new chemotherapy-free standard in frontline MCL, potentially allowing patients freedom from the burden of years of infusionsFull results from MANGROVE, including efficacy and safety, will be presented at an upcoming medical meeting; global regulatory submissions are planned for 2H 2026 BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306; NCT04002297) evaluating foundational BTK inhibitor BRUKINSA® (zanubrutinib) plus rituximab versus bendamustine plus rituximab (BR) in adult patients with previously untreated mantle cell lymphoma (MCL). MANGROVE is the first Phase 3, global, randomized trial to evaluate a BTK inhibitor-based chemotherapy-

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye